NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
Clinical Trials
14 trialsNCT03583255 2025-12-26
Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03324113 2025-08-05
Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors
Sanofi
Phase 1 Completed
NCT03578081 2025-04-06
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT03839940 2025-01-29
MIST
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT06118710 2024-09-25
DEXASTOP
Erasmus Medical Center
Phase 4 Recruiting
NCT05872893 2023-07-21
Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone
Immune Oncology Research Institute
Phase 3 Unknown
NCT02815319 2020-04-28
REaCT-dex
Ottawa Hospital Research Institute
Phase 4 Completed
NCT02265510 2020-04-17
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT02648490 2019-07-30
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
Henlix, Inc
Phase 1 Completed
NCT00201812 2017-12-06
Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02257476 2017-02-07
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
Emory University
Phase 1 Completed
NCT01909856 2015-12-04
The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT01640340 2013-11-07
Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)
Ohio State University Comprehensive Cancer Center
Phase NA Completed